Provexis plc (AIM:PXS)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 24.63M +83.6% |
| Revenue (ttm) | 871.27K -27.4% |
| Net Income | -603.80K |
| EPS | -0.00 |
| Shares Out | 2.35B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,232,585 |
| Open | 1.058 |
| Previous Close | 1.115 |
| Day's Range | 0.900 - 1.200 |
| 52-Week Range | 0.550 - 1.550 |
| Beta | 0.69 |
| Analysts | Hold |
| Price Target | 4.72 (+349.52%) |
| Earnings Date | Jul 30, 2026 |
About Provexis
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through e-commerce website ... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, Provexis's revenue was 1.29 million, an increase of 61.13% compared to the previous year's 801,964. Losses were -452,720, -22.78% less than in 2024.
Financial StatementsNews
AIM Market Roundup: Provexis, Geo Exploration, Sabien
Provexis, Geo Exploration, Sabien are today's top risers, while Bigblu Broadband, Empyrean Energy take the biggest fall on London's AIM